- Conditions
- Dry Eye Syndrome
- Interventions
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Glendale, California • Newport Beach, California • Rancho Cordova, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 455
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Interventions
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
- Conditions
- Dry Eye Disease
- Interventions
- PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 4
- States / cities
- Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- INV-102, Vehicle
- Drug
- Lead sponsor
- Invirsa, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rush, New York
- Conditions
- Seborrheic Keratosis
- Interventions
- A-101 Solution, Vehicle Solution
- Drug · Other
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Malvern, Pennsylvania
- Conditions
- Macular Degeneration
- Interventions
- Microplasmin, Placebo control
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acne Vulgaris
- Interventions
- FMX101 vehicle, Hydro-alcohol solution
- Drug · Other
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Allergic Conjunctivitis
- Interventions
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
- Conditions
- Dry Eye Disease
- Interventions
- K-161, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 45 more
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Papulopustular Rosacea
- Interventions
- Cromolyn Sodium, Normal Saline
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Actinic Keratosis
- Interventions
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator
- Drug · Device
- Lead sponsor
- DUSA Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Fremont, California • San Diego, California • Aventura, Florida + 10 more
- Conditions
- Diltiazem Skin Sensitivity.
- Interventions
- Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%)
- Drug
- Lead sponsor
- Ventrus Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Paramus, New Jersey
- Conditions
- Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
- Interventions
- Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution
- Drug · Other
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Roswell, Georgia
- Conditions
- Healthy
- Interventions
- CAY001, Placebo
- Drug · Other
- Lead sponsor
- Cayuga Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Interventions
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Allergic Conjunctivitis
- Interventions
- RX-10045, Vehicle for RX-10045 arm
- Drug
- Lead sponsor
- C.T. Development America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- CBX129801
- Drug
- Lead sponsor
- Cebix Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 22
- States / cities
- Escondido, California • Fresno, California • Irvine, California + 18 more
- Conditions
- Infections
- Interventions
- Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Lipopolysaccharide, LPS /Epinephrine, Placebo, Hydrocortisone
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Epiphora
- Interventions
- Atropine sulfate ophthalmic solution 0.005%, Vehicle arm
- Drug
- Lead sponsor
- Rehan Ahmed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas • Mesquite, Texas
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Newport Beach, California • Pittsburg, Kansas + 6 more
- Conditions
- IgA Nephropathy
- Interventions
- OMS721, Vehicle (D5W or saline)
- Biological · Other
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
- Drug
- Lead sponsor
- Aciex Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts